Payment overview · 2025
General Payments
$129,106.35
206 reported records · 28 companies
Healthcare provider profile · identity verified
V Sreenath Reddy, MD
Allopathic & Osteopathic Physicians|Thoracic Surgery (Cardiothoracic Vascular Surgery) · NASHVILLE, TN · NPI 1487787974
Verified facts
What the public records show
CMS Open Payments records show V Sreenath Reddy, MD received $129,106.35 in general payments during 2025 across 206 reported records.
AtriCure, Inc. accounted for 20.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 44 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AtriCure, Inc. | Unresolved — no canonical attribution shown | $25,994.10 | 20.1% | 34 | 2025 |
| AngioDynamics, Inc. | Unresolved — no canonical attribution shown | $22,433.73 | 17.4% | 39 | 2025 |
| Arthrex, Inc. | Unresolved — no canonical attribution shown | $22,352.95 | 17.3% | 13 | 2025 |
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $18,198.67 | 14.1% | 6 | 2025 |
| Solventum Corporation | Unresolved — no canonical attribution shown | $13,907.22 | 10.8% | 7 | 2025 |
| Artivion, Inc. | Unresolved — no canonical attribution shown | $8,960.88 | 6.9% | 24 | 2025 |
| Becton, Dickinson and Company | Unresolved — no canonical attribution shown | $8,548.04 | 6.6% | 6 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $2,412.27 | 1.9% | 12 | 2025 |
| Ethicon US, LLC | Unresolved — no canonical attribution shown | $1,804.16 | 1.4% | 2 | 2025 |
| Surgical Specialties Corporation (us), Inc. (dba Corza Medical) | Unresolved — no canonical attribution shown | $656.88 | 0.5% | 8 | 2025 |
| Ethicon Inc. | Unresolved — no canonical attribution shown | $585.00 | 0.5% | 1 | 2025 |
| Baxter Healthcare | Unresolved — no canonical attribution shown | $551.52 | 0.4% | 8 | 2025 |
| ClearFlow Inc. | Unresolved — no canonical attribution shown | $417.91 | 0.3% | 1 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $337.45 | 0.3% | 8 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $309.98 | 0.2% | 5 | 2025 |
| LSI SOLUTIONS INC | Unresolved — no canonical attribution shown | $306.54 | 0.2% | 1 | 2025 |
| Dilon Technologies, Inc. | Unresolved — no canonical attribution shown | $175.08 | 0.1% | 2 | 2025 |
| Music City Medical Technologies, LLC | Unresolved — no canonical attribution shown | $166.86 | 0.1% | 7 | 2025 |
| La Jolla Pharmaceutical Company | Unresolved — no canonical attribution shown | $161.99 | 0.1% | 5 | 2025 |
| Corcym Inc | Unresolved — no canonical attribution shown | $152.04 | 0.1% | 3 | 2025 |
| DePuy Synthes Sales Inc. | Unresolved — no canonical attribution shown | $150.01 | 0.1% | 1 | 2025 |
| Bolton Medical Inc | Unresolved — no canonical attribution shown | $149.00 | 0.1% | 1 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $122.27 | 0.1% | 6 | 2025 |
| Haemonetics Corporation | Unresolved — no canonical attribution shown | $112.65 | 0.1% | 2 | 2025 |
| Davol Inc. | Unresolved — no canonical attribution shown | $61.65 | 0.1% | 1 | 2025 |
| Zimmer Biomet Holdings, Inc. | Unresolved — no canonical attribution shown | $44.49 | 0.0% | 1 | 2025 |
| Acera Surgical, Inc. | Unresolved — no canonical attribution shown | $18.76 | 0.0% | 1 | 2025 |
| Octapharma USA, Inc. | Unresolved — no canonical attribution shown | $14.25 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $92,518.50 | 18 |
| Travel and Lodging | $15,317.15 | 45 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $11,600.00 | 1 |
| Food and Beverage | $9,670.70 | 142 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| SYNERGY ABLATION SYSTEM Normalized: synergy ablation system |
Device | AtriCure, Inc. | $25,847.29 | 30 | 2025 |
Source payment records
|
|||||
| ANGIOVAC Normalized: angiovac |
Device | AngioDynamics, Inc. | $19,852.47 | 30 | 2025 |
Source payment records
|
|||||
| PICO 7 Normalized: pico 7 |
Device | Smith+Nephew, Inc. | $18,198.67 | 6 | 2025 |
Source payment records
|
|||||
| PICO Normalized: pico |
Device | Smith+Nephew, Inc. | $17,335.70 | 4 | 2025 |
Source payment records
|
|||||
| Pico 14 Normalized: pico 14 |
Device | Smith+Nephew, Inc. | $16,737.50 | 1 | 2025 |
Source payment records
|
|||||
| Bair Hugger Normalized: bair hugger |
Device | Solventum Corporation | $13,012.01 | 3 | 2025 |
Source payment records
|
|||||
| Bair Paws Normalized: bair paws |
Device | Solventum Corporation | $11,600.00 | 1 | 2025 |
Source payment records
|
|||||
| SpotOn Normalized: spoton |
Device | Solventum Corporation | $11,600.00 | 1 | 2025 |
Source payment records
|
|||||
| BIOGLUE SURGICAL ADHESIVE Normalized: bioglue surgical adhesive |
Device | Artivion, Inc. | $8,560.40 | 9 | 2025 |
Source payment records
|
|||||
| ALPHAVAC Normalized: alphavac |
Device | AngioDynamics, Inc. | $2,581.26 | 9 | 2025 |
Source payment records
|
|||||
| SURGICEL NU-KNIT Normalized: surgicel nu knit |
Device | Ethicon Inc., Ethicon US, LLC | $2,340.00 | 2 | 2025 |
Source payment records
|
|||||
| EPIC Normalized: epic |
Device | Abbott Laboratories | $2,121.75 | 8 | 2025 |
Source payment records
|
|||||
| PREVENA Normalized: prevena |
Device | Solventum Corporation | $871.25 | 3 | 2025 |
Source payment records
|
|||||
| AMDS-Ascyrus Medical Normalized: amds ascyrus medical |
Device | Artivion, Inc. | $607.88 | 21 | 2025 |
Source payment records
|
|||||
| Pleuraflow System with FlowGlide Normalized: pleuraflow system with flowglide |
Device | ClearFlow Inc. | $417.91 | 1 | 2025 |
Source payment records
|
|||||
| ATRICLIP LAA EXCLUSION SYSTEM Normalized: atriclip laa exclusion system |
Device | AtriCure, Inc. | $377.61 | 5 | 2025 |
Source payment records
|
|||||
| PERCLOT Normalized: perclot |
Device | Baxter Healthcare | $372.64 | 6 | 2025 |
Source payment records
|
|||||
| ON-X AORTIC HEART VALVE WITH CONFORM-X SEWING RING AND EXTENDED HOLDER Normalized: on x aortic heart valve with conform x sewing ring and extended holder |
Device | Artivion, Inc. | $361.65 | 9 | 2025 |
Source payment records
|
|||||
| COR-KNOT Normalized: cor knot |
Device | LSI SOLUTIONS INC | $306.54 | 1 | 2025 |
Source payment records
|
|||||
| NAVITOR Normalized: navitor |
Device | Abbott Laboratories | $290.52 | 4 | 2025 |
Source payment records
|
|||||
| EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX Normalized: epi sense guided coagulation system with visitrax |
Device | AtriCure, Inc. | $263.14 | 2 | 2025 |
Source payment records
|
|||||
| MITRIS RESILIA Mitral Valve Normalized: mitris resilia mitral valve |
Device | Edwards Lifesciences Corporation | $256.31 | 6 | 2025 |
Source payment records
|
|||||
| ATRICURE CRYOICE CRYOSPHERE CRYOABLATION SYSTEM Normalized: atricure cryoice cryosphere cryoablation system |
Device | AtriCure, Inc. | $230.64 | 2 | 2025 |
Source payment records
|
|||||
| HEMOBLAST BELLOWS Normalized: hemoblast bellows |
Device | Dilon Technologies, Inc. | $175.08 | 2 | 2025 |
Source payment records
|
|||||
| GIAPREZA Normalized: giapreza |
Drug | La Jolla Pharmaceutical Company | $161.99 | 5 | 2025 |
Source payment records
|
|||||
| TRUMATCH Normalized: trumatch |
Device | DePuy Synthes Sales Inc. | $150.01 | 1 | 2025 |
Source payment records
|
|||||
| GELWEAVE Normalized: gelweave |
Device | Bolton Medical Inc | $149.00 | 1 | 2025 |
Source payment records
|
|||||
| THORAFLEX HYBRID Normalized: thoraflex hybrid |
Device | Bolton Medical Inc | $149.00 | 1 | 2025 |
Source payment records
|
|||||
| PREVELEAK Normalized: preveleak |
Device | Baxter Healthcare | $148.78 | 1 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $122.27 | 6 | 2025 |
Source payment records
|
|||||
| TEG6S HEMOSTASIS SYSTEM Normalized: teg6s hemostasis system |
Device | Haemonetics Corporation | $112.65 | 2 | 2025 |
Source payment records
|
|||||
| ACTIV.A.C. Normalized: activ a c |
Device | Solventum Corporation | $95.21 | 3 | 2025 |
Source payment records
|
|||||
| PERCEVAL Normalized: perceval |
Device | Corcym Inc | $93.89 | 2 | 2025 |
Source payment records
|
|||||
| Progel Applicator Spray Tips Normalized: progel applicator spray tips |
Device | Davol Inc. | $61.65 | 1 | 2025 |
Source payment records
|
|||||
| MI DETACH - AORTIC CROSS CLAMP - DELIVERY SYSTEM KIT Normalized: mi detach aortic cross clamp delivery system kit |
Device | Corcym Inc | $58.15 | 1 | 2025 |
Source payment records
|
|||||
| V.A.C.INSTILL Normalized: v a c instill |
Device | Solventum Corporation | $53.39 | 2 | 2025 |
Source payment records
|
|||||
| STRATAFIX Normalized: stratafix |
Device | Ethicon US, LLC | $49.16 | 1 | 2025 |
Source payment records
|
|||||
| VISTASEAL Normalized: vistaseal |
Biological | Ethicon US, LLC | $49.16 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRIS RESILIA AORTIC VALVE Normalized: inspiris resilia aortic valve |
Device | Edwards Lifesciences Corporation | $48.80 | 1 | 2025 |
Source payment records
|
|||||
| EVOQUE Normalized: evoque |
Device | Edwards Lifesciences Corporation | $32.34 | 1 | 2025 |
Source payment records
|
|||||
| CRYOVALVE SG PULMONARY HUMAN HEART VALVE Normalized: cryovalve sg pulmonary human heart valve |
Device | Artivion, Inc. | $30.38 | 2 | 2025 |
Source payment records
|
|||||
| Cardiac non-SynerGraft Normalized: cardiac non synergraft |
Device | Artivion, Inc. | $29.66 | 2 | 2025 |
Source payment records
|
|||||
| Restrata Wound Matrix Normalized: restrata wound matrix |
Device | Acera Surgical, Inc. | $18.76 | 1 | 2025 |
Source payment records
|
|||||
| FIBRYGA Normalized: fibryga |
Biological | Octapharma USA, Inc. | $14.25 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Metoprolol Tartrate | Metoprolol Tartrate | 94 | 48 |
| Furosemide | Furosemide | 56 | 35 |
| Amlodipine Besylate | Amlodipine Besylate | 44 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 20 | suppressed |
| Carvedilol | Carvedilol | 16 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 13 | suppressed |
| Cephalexin | Cephalexin | 13 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Losartan Potassium | Losartan Potassium | 12 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $129,106.35 · 206 records | AtriCure, Inc. | ACTIV.A.C., ALPHAVAC, AMDS-Ascyrus Medical, ANGIOVAC, ATRICLIP LAA EXCLUSION SYSTEM, ATRICURE CRYOICE CRYOSPHERE CRYOABLATION SYSTEM, BIOGLUE SURGICAL ADHESIVE, Bair Hugger, Bair Paws, COR-KNOT, CRYOVALVE SG PULMONARY HUMAN HEART VALVE, Cardiac non-SynerGraft, EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX, EPIC, EVOQUE, FIBRYGA, GELWEAVE, GIAPREZA, HEMOBLAST BELLOWS, INSPIRIS RESILIA AORTIC VALVE, LifeVest, MI DETACH - AORTIC CROSS CLAMP - DELIVERY SYSTEM KIT, MITRIS RESILIA Mitral Valve, NAVITOR, ON-X AORTIC HEART VALVE WITH CONFORM-X SEWING RING AND EXTENDED HOLDER, PERCEVAL, PERCLOT, PICO, PICO 7, PREVELEAK, PREVENA, Pico 14, Pleuraflow System with FlowGlide, Progel Applicator Spray Tips, Restrata Wound Matrix, STRATAFIX, SURGICEL NU-KNIT, SYNERGY ABLATION SYSTEM, SpotOn, TEG6S HEMOSTASIS SYSTEM, THORAFLEX HYBRID, TRUMATCH, V.A.C.INSTILL, VISTASEAL | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error